



## Anti-Ehrlichia canis ELISA Dog (IgG)



- High specificity due to the use of a recombinant antigen
- Efficient automation solutions available

### Technical data

<b>Antigen</b>	Recombinantly produced and highly purified Ehrlichia canis antigen
<b>Calibration</b>	Semiquantitative: Calculation of a ratio from the extinction of the sample and the extinction of the calibrator
<b>Result interpretation</b>	EUROIMMUN recommends interpreting results as follows: Ratio < 0.8: negative Ratio ≥ 0.8 to < 1.1: borderline Ratio ≥ 1.1: positive
<b>Sample dilution</b>	Canine serum or plasma, 1:101 in sample buffer
<b>Reagents</b>	Ready for use, with the exception of the wash buffer (10x), colour-coded solutions
<b>Test procedure</b>	30 min (37°C) / 30 min (37°C) / 15 min (room temperature), fully automatable
<b>Measurement</b>	450 nm, reference wavelength between 620 nm and 650 nm
<b>Test kit format</b>	96 break-off wells; kit includes all necessary reagents
<b>Order no.</b>	EI 220I-9601 GC

### Clinical significance

Ehrlichiosis is a disease which is transmitted to animals and humans by ticks. In canine ehrlichiosis, especially the pathogen Ehrlichia (E.) canis plays a role, which is mainly transmitted by the brown dog tick (Rhipicephalus sanguineus) and may lead to canine monocytic ehrlichiosis (CME). E. canis is a gram-negative, obligatory intracellular bacterium which mainly affects the mononuclear cells of the blood. CME occurs in tropical and moderate climates worldwide. The geographical distribution of E. canis increases with the further distribution of the vector tick which is accelerating due to climate change.

CME is a multisystemic disease which can manifest in acute, subclinical or chronic forms. After an incubation period of 1–3 weeks, an acute CME manifests amongst others by high fever, lethargy, weight loss, lymphadeno- and splenomegaly and haemorrhages. Frequently, eye damage occurs, which may lead even to complete blindness. Inflammatory changes or bleeding in the meninges may cause various CNS symptoms. Usually, after 2–4 weeks, the subclinical phase begins, in which the dogs appear to be healthy and without obvious symptoms, even though high titers of E. canis-specific IgG antibodies and changes in the blood values are detectable. In some dogs, this is succeeded by a chronic phase. Here the symptoms resemble those of acute CME again, but are often more pronounced.

### Diagnostic application

The direct microscopic detection of Ehrlichia is possible by Giemsa stain, but has only limited relevance since dogs are initially symptom-free despite high parasitemia and are only later presented to the veterinarian. Direct detection by PCR is indicated in the case of unclear serological findings and for therapy monitoring. Specific antibodies against E. canis are detectable by serology for approximately 14 days after infection and the serological antibody detection is the method of choice for laboratory diagnostics of CME. Owing to the use of a specific recombinant antigen, the Anti-Ehrlichia canis ELISA Dog (IgG) has a very high specificity and high sensitivity.



## Reproducibility

The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation using three samples. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on four determinations performed in six different test runs.

Serum	Intra-assay variation, n=20		Inter-assay variation, n=4x6	
	Mean value (ratio)	CV (%)	Mean value (ratio)	CV (%)
1	0.2	4.4	0.2	3.3
2	1.3	3.1	1.4	4.1
3	2.7	4.3	2.8	3.3



## Cross reactions

Cross reactions to antibodies against *Anaplasma phagocytophilum* are difficult to assess since double infections with both pathogens are frequent. Clear results could only be obtained when samples of experimentally infected dogs were used. Generally, cross reactions are unlikely to occur due to the use of a specific recombinant antigen. 50 canine samples with positive precharacterisation for antibodies against *Anaplasma phagocytophilum* (in-house ELISA) were investigated with the Anti-Ehrlichia canis ELISA Dog (IgG). Only one sample was evaluated as positive. It is unknown whether this sample originates from a dog with a double infection.



## Sensitivity and specificity

For the determination of sensitivity and specificity, a total of 132 canine samples were investigated with the EUROIMMUN Anti-Ehrlichia canis ELISA Dog (IgG). 17 samples originated from laboratory dogs with a negative expected value which was confirmed by the present test. The remaining 115 samples were precharacterised with a commercially available ELISA or immunofluorescence test for the detection of antibodies against *E. canis*. The results yielded a sensitivity of 92% and a specificity of 100%. Borderline results were not included in the evaluation.

n=132		Precharacterisation		
		positive	borderline	negative
EUROIMMUN Anti-Ehrlichia canis ELISA Dog (IgG)	positive	77	0	0
	borderline	1	0	3
	negative	7	0	44



## Literature

- Alleman AR, McSherry LJ, Barbet AF, Breitschwerdt EB, Sorenson HL, Bowie MV, Belanger M. Recombinant major antigenic protein 2 of *Ehrlichia canis*: a potential diagnostic tool. *J Clin Microbiol* (2001) 2494-2499.
- Donatien A, Lestoquard F. Existence en Algérie d'une *Rickettsia* du chien. *Bull Soc Pathol Exot.* (1935) 418-419.
- Groves MG, Dennis GL, Amyx HL, Huxsoll DL. Transmission of *Ehrlichia canis* to dogs by ticks (*Rhipicephalus sanguineus*). *Am J Vet Res* (1975) 937-940.
- Harrus S, Waner T. Diagnosis of canine monocytotropic ehrlichiosis (*Ehrlichia canis*): an overview. *Vet J* (2011) 292-296.
- Knowles TT, Alleman AR, Sorenson HL, Marciano DC, Breitschwerdt EB, Harrus S, Barbet AF, Belanger M. Characterization of the major antigenic protein 2 of *Ehrlichia canis* and *Ehrlichia chaffeensis* and its application for serodiagnosis of ehrlichiosis. *Clin Diagn Lab Immunol* (2003) 520-524.
- Little SE. Ehrlichiosis and anaplasmosis in dogs and cats. *Vet Clin North Am Small Anim Pract* (2010) 1121-1140.
- McBride JW, Corstvet RE, Gaunt SD, Boudreaux C, Guedry T, Walker DH. Kinetics of antibody response to *Ehrlichia canis* immunoreactive proteins. *Infect Immun* (2003) 2516-2524.
- Sainz A, Roura X, Miro G, Estrada-Pena A, Kohn B, Harrus S, Solano-Gallego L. Guideline for veterinary practitioners on canine ehrlichiosis and anaplasmosis in Europe. *Parasit Vectors* (2015) 75.
- Waner T, Harrus S, Bark H, Bogin E, Avidar Y, Keysary A. Characterization of the subclinical phase of canine ehrlichiosis in experimentally infected beagle dogs. *Vet Parasitol* (1997) 307-317.
- Waner T, Harrus S, Jongejan F, Bark H, Keysary A, Cornelissen AW. Significance of serological testing for ehrlichial diseases in dogs with special emphasis on the diagnosis of canine monocytic ehrlichiosis caused by *Ehrlichia canis*. *Vet Parasitol* (2001) 1-15.